Mergers and acquisitions

BIND accepts Pfizer bid following bankruptcy

Bid of $20 million may be enough to acquire all of BIND’s assets.

BIND accepts Pfizer bid following bankruptcy

https://pharmaphorum.com/news/bind-accepts-pfizer-stalking-horse-bid-following-motion-sell-assets/

Celgene’s new CEO weighs in to drug pricing debate

Celgene’s new CEO Mark Alles discusses pricing and M&A, criticises Valeant’s approach. Richard Staines reports. Richard Staines Celgene’s

Celgene’s new CEO weighs in to drug pricing debate

https://pharmaphorum.com/views-and-analysis/celgene-s-new-ceo-weighs-in-to-drug-pricing-debate/

Pharma news round-up: Pfizer-Allergan merger scrapped, Gilead to buy Nimbus Apollo, WHO diabetes campaign and more

A round-up of this week’s top pharma and healthcare news – plus reaction from social media. Marco Ricci

Pharma news round-up: Pfizer-Allergan merger scrapped, Gilead to buy Nimbus Apollo, WHO diabetes campaign and more

https://pharmaphorum.com/views-and-analysis/pharma-news-round-up-pfizer-allergan-merger-scrapped-gilead-to-buy-nimbus-apollo-who-diabetes-campaign-and-more/

UCB: growing sales and growing bones

The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen

UCB: growing sales and growing bones

https://pharmaphorum.com/articles/ucb-growing-sales-and-growing-bones/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Search

Advanced Search

Trending

Mergers and acquisitions

BIND accepts Pfizer bid following bankruptcy

Celgene’s new CEO weighs in to drug pricing debate

Pharma news round-up: Pfizer-Allergan merger scrapped, Gilead to buy Nimbus Apollo, WHO diabetes campaign and more

UCB: growing sales and growing bones